Previous 10 | Next 10 |
2023-03-06 11:10:18 ET Alaunos Therapeutics ( NASDAQ: TCRT ) is scheduled to announce Q4 earnings results on Tuesday, March 7th, before markets open. The consensus EPS Estimate is -$0.07 (-40.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 1 year, TCRT ...
2023-03-06 10:17:11 ET Major earning expected before the bell on Tuesday include: Canaan ( CAN ) DICK'S Sporting Goods ( DKS ) Sea ( SE ) Alaunos Therapeutics ( TCRT ) Thor Industries ( THO ) For further details see: Notable earnings befor...
HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended D...
Summary A third patient dosed last quarter should have 12-week data next month. However, the company promised a mid-year readout. Its cell therapy library is expanding, although really not doubling its potential market. Last month, Alaunos Therapeutics ( TCRT ) highlighted...
Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR discovery platform Increasing patient enrollment to advance TCR-T Library Program towards Phase 2 using high value TCRs targeting c...
Thinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics? PR Newswire NEW YORK , July 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ...
We’re in the final stretch of June 2022 and the last few days of the second quarter. Gross Domestic Product results for the quarter and additional CPI data are also due out before July. Whether they reveal a recession, higher inflation, or something completely different may not matte...
Clinical-stage biotech Alaunos Therapeutics (NASDAQ:TCRT) announced on Monday that the company and the National Cancer Institute (NCI), agreed to extend their partnership for personalized TCR-T cell therapies to 2025. Per the terms of the Cooperative Research and Development Agreement (CRADA)...
HOUSTON, June 27, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the Company has extended its Cooperative Research and Development Agree...
There’s only one week left until we turn the page on June and the second quarter. With GDP numbers and more CPI data expected to show the progress in curbing inflation, the market’s risk appetite seems to change daily. But one of the more static trends in the stock market toda...
News, Short Squeeze, Breakout and More Instantly...
Alaunos Therapeutics Inc. Company Name:
TCRT Stock Symbol:
NASDAQ Market:
Alaunos Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...